Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072943 · ClinicalTrials.gov registry record · Phase 2
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
A Phase 2 study, sponsored by Facet Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT00072943 is a Phase 2 study that has completed, run by Facet Biotech. The registered enrollment target is 175 participants.
The verdict
NCT00072943, a Phase 2 study, has completed, sponsored by Facet Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
The purpose of the HARMONY study is to assess the safety and efficacy of an investigational drug called HuZAF, in patients with moderate to severe Crohn's disease (CD). HuZAF is a humanized anti-Interferon-gamma (anti-IFN-γ) monoclonal antibody, which binds and blocks IFN-γ, a protein in the immune system that is involved in inflammation. Antibodies are proteins normally produced by our immune system to help fight off foreign substances. Scientists have been able to make therapeutic humanized monoclonal antibodies, similar to the antibodies in our bodies, to target diseases.
Interventions
- DRUG anti-Interferon-gamma monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2002-03 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00072943
The ClinicalTrials.gov registry entry for NCT00072943 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anti-Interferon-gamma monoclonal antibody is the first listed.
NCT00072943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00072943 about?
NCT00072943 is a clinical study titled "A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease". The purpose of the HARMONY study is to assess the safety and efficacy of an investigational drug called HuZAF, in patients with moderate to severe Crohn's disease (CD). HuZAF is a humanized anti-Interferon-gamma (anti-IFN-γ) monoclonal antibody, which binds and blocks IFN-γ, a protein in the immune ...
What is the current status of trial NCT00072943?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2002-03. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00072943?
The interventions under investigation include: anti-Interferon-gamma monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT00072943?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.